Key Drivers
- High Margins
- Strong Cash Flow
- Solid Liquidity
AIAI Summary
INCY should now be viewed as a franchise-extension story—not just Jakafi optionality—because Jakafi XR, Opzelura, and Zynyz can broaden growth, but the stock likely won't rerate until those newer assets prove they can scale fast enough to offset Jakafi concentration risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High Margins
- •Strong Cash Flow
- •Solid Liquidity
INCY combines strong margins, robust cash flow, and a fortress balance sheet, though near-term operating efficiency has softened and the stock looks fairly valued rather than cheap.
Price Behavior
Key Price Behavior Insights:
- •Mid-90s support
- •Repeated $100 failure
- •Short-term pullback
INCY has drifted lower over the last month, holding a choppy mid-$90s base but repeatedly failing near $100, leaving $94.65–$95.00 as the key support to watch and $100 as near-term resistance.
Sharp rebound from $94.65 to $100.32, then a quick fade back into the mid-$90s
Sentiment & News
Key News Insights:
- •Earnings beat
- •Growth momentum
- •Institutional buying
Incyte's recent news flow is decisively bullish, led by a Q1 earnings beat and strong revenue growth from Jakafi and Opzelura, reinforced by upbeat momentum/value coverage and steady institutional buying.
The news supports a positive near-term outlook for Incyte, with solid fundamentals and sustained investor interest likely to underpin sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings